CN106214990B - Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent - Google Patents
Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent Download PDFInfo
- Publication number
- CN106214990B CN106214990B CN201610825041.3A CN201610825041A CN106214990B CN 106214990 B CN106214990 B CN 106214990B CN 201610825041 A CN201610825041 A CN 201610825041A CN 106214990 B CN106214990 B CN 106214990B
- Authority
- CN
- China
- Prior art keywords
- treatment
- shoulder
- capsules
- zhuifengtougu
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 title claims abstract description 35
- 206010008334 Cervicobrachial syndrome Diseases 0.000 title claims abstract description 34
- 239000002775 capsule Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims description 29
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 90
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 12
- 241000758794 Asarum Species 0.000 claims description 9
- 229910052956 cinnabar Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 241000173529 Aconitum napellus Species 0.000 claims description 5
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 240000007311 Commiphora myrrha Species 0.000 claims description 5
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 5
- 241001465251 Ephedra sinica Species 0.000 claims description 5
- 239000004863 Frankincense Substances 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 241000237636 Pheretima Species 0.000 claims description 5
- 229940023019 aconite Drugs 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000003717 Boswellia sacra Nutrition 0.000 claims 1
- 240000007551 Boswellia serrata Species 0.000 claims 1
- 235000012035 Boswellia serrata Nutrition 0.000 claims 1
- 241001251949 Xanthium sibiricum Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 25
- 208000011580 syndromic disease Diseases 0.000 abstract description 21
- 210000001364 upper extremity Anatomy 0.000 abstract description 10
- 206010067484 Adverse reaction Diseases 0.000 abstract description 7
- 230000006838 adverse reaction Effects 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000006011 Stroke Diseases 0.000 description 26
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 238000007427 paired t-test Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010008190 Cerebrovascular accident Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 206010019468 Hemiplegia Diseases 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000717739 Boswellia sacra Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 244000197580 Poria cocos Species 0.000 description 4
- 235000008599 Poria cocos Nutrition 0.000 description 4
- 229940074869 marquis Drugs 0.000 description 4
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010832 independent-sample T-test Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- -1 mixes Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the new opplications that a kind of compound Chinese medicinal preparation Zhuifengtougu capsules are used to treat shoulder-hand syndrome after stroke.The present invention passes through the clinical observation on the therapeutic effect to Zhuifengtougu capsules for patients with shoulder-hand syndrome after stroke, it was found that Zhuifengtougu capsules treat shoulder-hand syndrome after stroke, the extremely significant reduction SHS scale score of energy compared with before administration, pretherapy and post-treatment TCM syndrome integral, pain scores, upper limb Fugl-Meyer scoring, ADL scoring, NIHSS scoring also have extremely significant difference, obvious adverse reaction is had no in treatment, so that it is determined that the validity and safety of Zhuifengtougu capsules treatment shoulder-hand syndrome after stroke.The present invention is that the treatment of shoulder-hand syndrome after stroke adds new content.
Description
Technical field
The present invention relates to field of medicaments, and in particular to a kind of compound Chinese medicinal preparation Zhuifengtougu capsules newly answering clinically
With.
Background technique
Shoulder-hand syndrome (shoulder-hand syndrome, SHS) is also known as sympathetic reflex dystrophy
(reflex sympathetic dystrophy, RSD) refers to that patient suffers from the unexpected edema pain of hand and shoulder arthralgia, and makes
Hand function limitation.Because of the heavier concurrent contractura of pain, become the hindering factor of rehabilitation.The syndrome often betides post-stroke 1~3
In a month, incidence is about 12.5%~70%, and the difference of incidence may be related with diagnostic criteria difference.It usually influences one
A limbs, but any position of multiple limbs or body can also be influenced sometimes, only 20% patient can restore completely pervious
Activity, such as not appropriate treatment, the permanent deformity that will lead to shoulder and hand, refer to.
At present the primary treatments of shoulder-hand syndrome include Physical rehabilitation treatment, sympathetic block, closed treating,
Oral drug therapy etc..But because its pathogenesis is not yet clear, so far still without specific treatment method.Traditional Chinese medicine is treated
The prevention and treatment of shoulder-hand syndrome after stroke adds new content, has distinct characteristic and advantage, is that post-stroke patients with shoulder hand is comprehensive
The critical treatment means of simulator sickness clinical treatment.The means of existing Chinese traditional treatment shoulder-hand syndrome are mainly acupuncture, stifling etc.,
Have that be aided with traditional Chinese herbal decoction for oral administration, but rarely has the report of Chinese patent drugs for treatment SHS.
Zhuifengtougu capsules of the present invention are the compound Chinese medicinal preparation listed.Zhuifengtougu capsules are by aconiti preparata,radix, perfume (or spice)
It is attached (system), Rhizoma Chuanxiong, Chinese ephedra, wild aconite root, gentianae macrophyllae, Radix Angelicae Sinensis, rde bean, Rhizoma Et Radix Notopterygii, radix paeoniae rubra, asarum, Rhizoma Arisaematis (processed), the root of Dahurain angelica, Radix Glycyrrhizae, white
Art (stir-fry), myrrh (system), olibanum (system), pheretima, Poria cocos, ramulus cinnamomi, Rhizoma Gastrodiae, rhizoma nardostachyos, radix saposhnikoviae, cinnabar composition, it is granted
Major function are as follows: degrading the channel, wind-damp dispelling, dispelling cold of easing pain are used for treating arthralgia due to cold and dampness, four limbs numbness pain, neural paralysis is numb in every limb.
There is not been reported for treating shoulder-hand syndrome after stroke for Zhuifengtougu capsules.
Summary of the invention
The present invention is intended to provide a kind of new application of Zhuifengtougu capsules, i.e. Zhuifengtougu capsules are used clinically for treating
The application of shoulder-hand syndrome after stroke.
The technical solution adopted by the present invention to solve the technical problems is: by clinical observation on the therapeutic effect, determining that it treats brain
The validity and safety of shoulder-hand syndrome after stroke.
The prescription (1000) of the compound Chinese medicinal preparation Zhuifengtougu capsules are as follows: aconiti preparata,radix 48.1g, rhizoma cyperi (system)
48.1g, Rhizoma Chuanxiong 48.1g, Chinese ephedra 48.1g, wild aconite root 48.1g, gentianae macrophyllae 24g, Radix Angelicae Sinensis 24g, rde bean 48.1g, Rhizoma Et Radix Notopterygii 48.1g,
Radix paeoniae rubra 48.1g, asarum 48.1g, Rhizoma Arisaematis (processed) 48.1g, root of Dahurain angelica 48.1g, Radix Glycyrrhizae 48.1g, Rhizoma Atractylodis Macrocephalae (stir-fry) 24g, myrrh (system)
9.6g, olibanum (system) 24g, pheretima 48.1g, Poria cocos 96.2g, ramulus cinnamomi 24g, Rhizoma Gastrodiae 24g, rhizoma nardostachyos 24g, radix saposhnikoviae 24g, cinnabar
38.5g.Its preparation method are as follows: above 24 taste or is ground into impalpable powder at cinnabar powder-refining with water；Asarum extracts volatile oil, the water after distillation
The another device of solution is collected, and 22 taste such as remaining Rhizoma Chuanxiong adds water to cook secondary, 2 hours first times, and second 1 hour, collecting decoction
And asarum distillation after aqueous solution, stand 2 hours, filtration, filtrate decompression be condensed into relative density be 1.25(60 DEG C survey) it is thick
Cream is added cinnabar fine powder and appropriate amount of starch, is dried, crushed into fine powder, mixes, particle is made, dry, sprays into volatile oil, mixes,
Be packed into capsule, be made 1000 to get.
The title for having hemiplegia, hemiplegia etc. different in TCM Document "Nei Jing" is recorded, wherein with shoulder after a hemiplegia disease and apoplexy
The symptom of hand syndrome is rather similar, and in " Ling Shu Miraculous Pivot or Divine Axis pyreticosis " record, " hemiplegia, body does not have to and pain partially, and speech is constant, and will is not random, disease
Dividing between the natural fibre line of meat.Have cloud " Ling Shu Miraculous Pivot or Divine Axis Ci Jiezhen is evil ": " empty evil partially objective body half, enters to occupy battalion in deep and defend, battalion, which defends, slightly to decline, then very
Gas is gone, pathogen remaining alone, and it is hemiplegia for sending out ".Therefore traditional Chinese medicine think apoplexy lower body it is unsuccessful mostly because of blood stagnancy due to deficiency of QI, the train of thought stasis of blood is stagnant leads
It causes.Have again " Synopsis Golden Chamber apoplexy severe and migratory arthralgia " " husband's wind is referred to as disease, works as hemiplegia, or but arm it is unsuccessful, this is numbness ".This says
Bright apoplexy lower body is unsuccessful in addition to deficiency of vital energy blood is weak, the train of thought stasis of blood is stagnant, in close relations with exopathogen invasion, can belong to rheumatism scope.Shoulder hand
Syndrome is using pain, oedema as primary symptom, just because of suffering limb deficient qi and blood, caused by the train of thought stasis of blood is stagnant and the invasion of wind-engaging cold-dampness.Therefore brain
Shoulder-hand syndrome after stroke belongs to " rheumatism " scope.Apoplexy belongs to severe crisis, saps one's vitality after apoplexy, and qi and blood is more empty, blood
More, passages through which vital energy circulates retardance, QI-blood circulation is unsmooth for the stasis of blood, and then qi and blood difficulty is up to four ends for sering retardance, and the mistake of tendon and vessel muscle is flourish, at this time wind-cold damp pathogen
It easily takes advantage of a weak point in opponent's defence and invades muscle, channels and collaterals, joint, the card of the phlegm-blood stasis that becomes a common practice resistance, " not general rule pain ", " not Rong Ze pain ", therefore there is hemiplegia side
Shoulder, elbow, wrist distending pain.Unfavorable through tunnel due to wind phlegm stasis blocking, " blood unfavorable then be water ", aqueous is overflowed skin, and the water stasis of blood mutually tie therefore wrist is carried on the back
And finger swelling.So shoulder-hand syndrome is disease with insufficiency of vital energy and blood, wind-cold-dampness arthralgia, wind phlegm stasis blocking and cold sensation of the genitalia venereal disease reason product accumulation
Machine feature, wherein wind phlegm stasis blocking is interpretation of the cause, onset and process of an illness key link.It is promoting blood circulation and removing obstruction in channels with dispelling wind resolving sputum in therapy, based on inducing diuresis for removing edema.It chases after
The deep capsule of wind by aconiti preparata,radix, rhizoma cyperi (system), Rhizoma Chuanxiong, Chinese ephedra, wild aconite root, gentianae macrophyllae, Radix Angelicae Sinensis, rde bean, Rhizoma Et Radix Notopterygii, radix paeoniae rubra, asarum,
Rhizoma Arisaematis (processed), the root of Dahurain angelica, Radix Glycyrrhizae, Rhizoma Atractylodis Macrocephalae (stir-fry), myrrh (system), olibanum (system), pheretima, Poria cocos, ramulus cinnamomi, Rhizoma Gastrodiae, rhizoma nardostachyos, radix saposhnikoviae,
The 24 taste Chinese medicinal composition such as cinnabar, aconiti preparata,radix, wild aconite root, gentianae macrophyllae dispelling wind and eliminating dampness, stopping numbness pain are monarch drug in a prescription altogether in side；Chinese ephedra, the root of Dahurain angelica, osmanthus
Branch, notopterygium wind dispelling inducing diaphoresis analgesic, pheretima, Rhizoma Gastrodiae dispelling wind and removing obstruction in the meridians are ministerial drug altogether；Olibanum, myrrh, radix paeoniae rubra, Rhizoma Chuanxiong, Radix Angelicae Sinensis promoting blood circulationization
The stasis of blood；Poria cocos, Rhizoma Atractylodis Macrocephalae invigorating the spleen eliminating dampness and diuresis；Asarum sweating clearing damp, rhizoma arisaematis is eliminating dampness and eliminating phlegm, rde bean dehumidifying Li Shui, removing toxicity for detumescence；
Rhizoma cyperi, rhizoma nardostachyos open it is strongly fragrant be amusing, promoting qi circulation and relieving pain；Radix Glycyrrhizae is that assistant makes coordinating the drug actions of a prescription.It is stagnant for prescription feature that its cannot be opened with non- great Xin.It is all
Medicine shares, altogether long memorial weathering phlegm, function promoting blood circulation and removing obstruction in channels, inducing diuresis for removing edema.
The usage and dosage of Zhuifengtougu capsules treatment shoulder-hand syndrome after stroke: it is oral, 4 tablets each time, 2 times a day.It treats
Journey: with 28 days for 1 course for the treatment of.
Preliminary clinical observation result shows: Zhuifengtougu capsules treat shoulder-hand syndrome after stroke, with phase before administration
Reduction SHS scale score more extremely significant than energy, total significant effective percentage is 63.33%, total effective rate 93.33%；In pretherapy and post-treatment
Doctor's disease integration, pain scores, upper limb Fugl-Meyer scoring, ADL scoring, NIHSS scoring also have extremely significant difference.Treatment
In have no obvious adverse reaction.The above results show that Zhuifengtougu capsules treatment shoulder-hand syndrome after stroke has clear improvement
The effect of suffering limb crymodynia and neurologic impairment symptom, safely and effectively.
Meaning of the present invention is the treatment for prompting Zhuifengtougu capsules to can be used for shoulder-hand syndrome after stroke, develops
The potential novel clinical use for having listed compound Chinese medicinal preparation Zhuifengtougu capsules, is worthy of further application.The present invention is brain
The treatment of shoulder-hand syndrome after stroke adds a kind of new method.
Specific embodiment
Below with reference to embodiment, the invention will be further described.
Embodiment: the clinical observation on the therapeutic effect of Zhuifengtougu capsules treatment shoulder-hand syndrome after stroke.
One, data and method.
1 clinical data.
1.1 case sources: all cases were derived from from May, 2012 to Hunan Province's Chinese medicine study during in March, 2013
60 patients with shoulder-hand syndrome after stroke for meeting this research " being included in case standard " of inpatient department, affiliated hospital, institute and outpatient service.
1.2 Western medicine diagnostic criteria.
1.2.1 cerebral apoplexy diagnostic criteria: referring to the standard of the 4th national cerebrovascular disease academic conference revision.
1.2.2 shoulder-hand syndrome diagnostic criteria: the diagnosis of Post stroke SHS is not sought unity of standard still at present, our references
Stroke rehabilitation research center shoulder-hand syndrome diagnostic criteria in 1996 and Kozin standard.
The shoulder-hand syndrome diagnostic criteria that China Rehabilitation Research Center formulates: patient has cranial vascular disease；Unilateral shoulder hand pain,
Flush, Pi Wen rise；Hand swelling, finger flexion are limited；Evidence of the part without wound, infection, also without peripheral angiopathy
Evidence.
Kozin standard: SHS diagnostic criteria: 4 item rating >=8 point.
1.3 TCM syndrome diagnostic criteria.
Standards of Chinese Medical Syndrome Differentiation is dialectical with reference to the Wind-phlegm syndrome that 2002 " new Chinese medicine guideline of clinical investigations " is formulated
Standard determines: (1) primary symptom: 1. shoulder pain is affected by the cold or meets that rainy days, the pain increased；2. ipsilateral wrist, finger swelling, pain
Bitterly；3. joint motion is limited.(2) minor symptom: 1. numb limb；2. hemiplegia；3. sluggish speech or in silence；4. dispute is crooked；
5. limbs are anxious by force；6. abundant expectoration and glue；7. mouth is light and greasy；8. indigestion and loss of appetite gastral cavity is bored.(3) tongue vein: 1. tongue nature is light or light dark；2. tongue fur it is white or
It is white greasy；3. wiry and rolling pulse.The above syndrome at least has primary symptom 2, minor symptom 4, can diagnose with reference to tongue vein.
1.4 test case standards.
1.4.1 it is included in standard: (1) meeting cerebral apoplexy Western medicine diagnostic criteria (initial cerebral infarction), Chinese medicine (Wind-phlegm syndrome)
Diagnostic criteria, shoulder-hand syndrome (I phase) diagnostic criteria, shoulder-hand syndrome marking scales score >=8 points；(2) age is 18~75
Year；(3) within onset 2 weeks to 6 months；(4) Clear consciousness, vital sign are steady；(5) it is voluntarily used as study subject and signs and know
Feelings letter of consent person.Conditions above must meet simultaneously can just be included in.
1.4.2 exclusion criteria: (1) cerebral hemorrhage；(2) ache before cerebral apoplexy with shoulder caused by scapulohumeral periarthritis, cervical diseases
Pain person, rheumatoid arthritis；(3) deaf, aphasia cause is unable to Communicator；(4) week caused by complication with diabetes, malnutrition etc.
Enclose neuropathy subjects；(5) age is in under-18s or 75 years old or more；(6) merge intentionally, liver, the serious disease such as kidney and hemopoietic system
Suffer from or the gestational period, breast feeding women and on the occasion of menstrual period person；(7) it is associated with nerve, mental disease, or is reluctant partner；(8) mistake
Quick constitution or to a variety of drug allergy persons；(9) there are obvious and folder card or complication or the state of an illness critical, it is difficult to the validity of new drug
Make definite estimator with safety；(10) it is once treated in the recent period using similar drugs, such as takes related or phase antagonism medicine
Object causes curative effect of medication to be difficult to judgement person；(11) because adverse reaction is not resistant to treat or has other reasons that cannot continue as required
Complete curer.Conditions above has the person of meeting, and cannot be included in.
1.4.3 reject standard: (1) discovery does not meet and is included in standard person after being included in, or the person that meets exclusion criteria；(2) random
A drug person was not taken after change；(3) without any experimental record person after being randomized；(4) merge and be forbidden to use using this programme
Chinese and western drugs, affect the treatment and safe sex determination person.The case of rejecting answers illustration, and observation table should retain for future reference.
1.4.4 fall off standard: (1) patient voluntarily exits (too poor, adverse reaction of curative effect etc.)；(2) researcher enables it exit
(compliance is poor；There is concomitant disease；Serious adverse events).The case to fall off should record reason in detail, and by its last time
The switching of curative effect testing result is that final result is analyzed, and observation table should retain for future reference.
2 research methods.
The grouping of 2.1 cases.
Inpatient 60.It is grouped at random using random grouping sheet, 60 patients of the standard of being included in will be met, by just
Serial number is examined, is randomly divided into treatment group and control group, every group 30.Group technology: by 60 patient codes (1~60), from
First number (15) of the 9th row of table of random number starts, and searches from left to right, the odd number less than or equal to 60 is divided into treatment group (A
Group), it is totally 30, remaining to be divided into control group (B group), it is also 30.
2.2 treatment method.
2.2.1 therapeutic agent.
Zhuifengtougu capsules: it is produced by Hunan De Kang Pharmacy stock Co., Ltd, authentication code: national drug standard
Z20083219, every 0.26g(lot number 111202 of specification).
Control group: Huoluo Xiaotong Capsules: by being produced by Hunan Fang Shengtang pharmaceutical Co. Ltd, authentication code national drug standard
Z20080143, every 0.35g(lot number 111004 of specification).
2.2.2 method of administration.
Zhuifengtougu capsules: it 4 tablets each time, 2 times a day, takes orally.
Huoluo Xiaotong Capsules: it 4 tablets each time, 3 times a day, takes orally.
2.2.3 the course for the treatment of: with 28 days for 1 course for the treatment of.
2.2.4 it and with therapy controls: being not added during the above observation with other Chinese and Western therapeutic agents or other treatment means.It sees
Occur any adverse reaction during examining and take which kind for the treatment of measures that should also record faithfully.
3 observation indexs and record.
3.1 safety observation indexs: (1) general Clinical Project: heart rate, pulse, blood pressure, breathing, before and after treatment each inspection
It surveys primary；(2) blood routine, urine routine and stool routine examination, liver function (ALT), renal function (BUN, Cr), coagulation function, cardiac muscle
Enzyme, electrocardiogram, each detection record is primary before and after treatment；(3) such as to the adverse reaction being likely to occur: fear is cold, generates heat, anaphylaxis
Fash, back severe pain, abdominal distension etc., record at any time.
3.2 health giving quality observation indexs: (1) SHS scores, and assesses scale (Shoulder-hand by shoulder-hand syndrome
Syndrome score) evaluation；(2) Chinese medicine syndrome integral；(3) pain scores, using visual analogue scale (Visual
Analogous Scale, VAS) it is evaluated；(4) motor functional evaluation simplifies Fugl-Meyer using upper limb and moves function
It can scoring；(5) activity of daily living ADL is evaluated using the Barthel index (MBI) of improvement；(6) US National health
Institute's neurological deficits score (NIHSS)；(7) electromyogram.
The above index is primary in each detection record before and after treatment.Evaluating member is that treatment group or control group are not known to patient
Feelings.
4 efficacy evaluations.
Referring to Kozin standard, with shoulder-hand syndrome assessment scale as pretherapy and post-treatment standards of grading.
Recovery from illness: each symptom disappears after treatment, and syndrome integral value reduces >=95%.
Effective: each symptom is substantially reduced after treatment, and syndrome integral value reduces >=70%, < 95%.
Effective: each symptom is mitigated after treatment, and syndrome integral value reduces >=30%, < 70%.
Invalid: for each symptom without mitigating or having exacerbation, syndrome integral value reduces < 30% after treatment.
Curative effect index calculation formula (Nimodipine method): [(pre-treatment score-post treatment integral) ÷ pre-treatment score] ×
100%。
5 statistical processing methods.
It is analyzed using SPSS16.0 statistical software.In relation to examining the test statistics provided and its corresponding P value, bilateral is used
It examines, is statistically significant with P < 0.05.Measurement data indicates that enumeration data, grade are provided with mean ± standard deviation (X ± s)
Material is indicated with contingency table frequency.If measurement data meets normal distribution, leading homogeneity test of variance, variance together then match by interior use of group
The t compared is examined, independent samples t-test is used between group.Enumeration data is examined using X2.Do not meet normal distribution measurement data and
The rank sum test that ranked data use two samples to compare.
Two, result and analysis.
The analysis of 1 general information.
Gender, age are carried out to two groups of cases before treatment, the course of disease compares, and difference is not statistically significant.To two before treatment
Shoulder-hand syndrome scoring, Chinese medicine syndrome integral, pain scores, upper extremity function scoring, daily life function scoring, neural function between group
Energy defect scoring is compared, and difference is not statistically significant.Illustrate to be comparable between two groups of groups.
2 therapeutic evaluatioies.
2.1 two groups of case treatment SHS scale scores compare.
1 two groups of table pretherapy and post-treatment SHS scorings compare (point,).
Compare row paired t-test in the pretherapy and post-treatment SHS scoring group for the treatment of group, there is significant differences (t=14.4271, P
< 0.01), compare row paired t-test in the pretherapy and post-treatment SHS scoring group of control group, there is significant differences (t=9.79641, P
< 0.01), prompt two groups of treatments effective；Two groups of SHS scoring comparison among groups row independent samples t-tests, have very significant poor after treatment
Different (t=- 4.15087, P < 0.01), illustrates that treatment group is substantially better than control group in the reduction amplitude that SHS scores.
The pretherapy and post-treatment SHS curative effect of 2.2 two groups of cases compares.
2 two groups of table pretherapy and post-treatment SHS curative effects compare [(%)].
| Group | Number of cases | Recovery from illness | It is effective | Effectively | In vain | Total effective rate (%) total effective rate (%) |
| Treatment group | 30 | 4 | 15 | 10 | 1 | 63.33 93.33 |
| Control group | 30 | 1 | 11 | 14 | 4 | 40.00 86.67 |
Curative effect compares (Ridit analysis): u=1.97519, P < 0.05 between two groups.
Illustrate that treatment group is significant in efficacy better than control group.
2.3 two groups of pretherapy and post-treatment Chinese medicine syndrome integrals of case compare.
3 two groups of pretherapy and post-treatment Chinese medicine syndrome integrals of table compare (point,).
Treatment group pretherapy and post-treatment Syndrome in TCM marquis product grouping internal ratio relatively row paired t-test, have significant differences (t=
21.2645, P < 0.01), the pretherapy and post-treatment Syndrome in TCM marquis product grouping internal ratio relatively row paired t-test of control group, has very significant poor
Different (t=15.3959, P < 0.01) prompts two groups of treatments effective；Two groups of Syndrome in TCM marquis integrate comparison among groups row t in groups after treatment
It examines, has significant differences (t=- 4.44322, P < 0.05), illustrate treatment group in the reduction amplitude that Syndrome in TCM marquis integrates
It is substantially better than control group.
2.4 two groups of pretherapy and post-treatment pain scores of case compare.
4 two groups of table pretherapy and post-treatment VAS scorings compare (point,).
Compare row paired t-test in the pretherapy and post-treatment pain scores group for the treatment of group, there is significant differences (t=19.658, P
< 0.01), compare row paired t-test in the pretherapy and post-treatment pain scores group of control group, there is significant differences (t=17.2255, P
< 0.01), prompt two groups of treatments that can relieve pain；Two groups of pain scores comparison among groups row independent samples t-tests, have very after treatment
Significant difference (t=2.45373, P < 0.05) shows that the curative effect for the treatment of group's alleviation limb pain is substantially better than control group.
The pretherapy and post-treatment upper limb Fugl-Meyer scoring of 2.5 two groups of cases is compared.
5 two groups of table pretherapy and post-treatment upper limb Fugl-Meyer scorings compare (± s).
Compare row paired t-test in the pretherapy and post-treatment upper limb Fugl-Meyer scoring group for the treatment of group, there are significant differences
(t=15.1645, P < 0.01), the interior relatively row paired t-test of the pretherapy and post-treatment upper limb Fugl-Meyer scoring group of control group, has very
Significant difference (t=11.6957, P < 0.01)；Two groups of upper limb Fugl-Meyer scorings carry out comparison among groups after treatment, and difference has
Statistical significance (t=3.80633, P < 0.01) illustrates that two groups can improve upper extremity function, and treatment group's curative effect is substantially better than control
Group.
The pretherapy and post-treatment ADL scoring of 2.6 two groups of cases is compared.
6 two groups of table pretherapy and post-treatment ADL scorings compare (± s).
Compare row paired t-test in the pretherapy and post-treatment ADL scoring group for the treatment of group, there is significant differences (t=- 14.250, P
< 0.01), relatively row paired t-test in the pretherapy and post-treatment ADL scoring group of control group, have significant differences (t=- 14.994, P <
0.01)；Two groups of ADL scorings carry out comparison among groups after treatment, and no significant difference (t=0.361, P > 0.05) shows two
Group can improve daily life index, but two groups of no significant differences.
The pretherapy and post-treatment NIHSS scoring of 2.7 two groups of cases is compared.
7 two groups of table pretherapy and post-treatment NIHSS scorings compare (± s).
Relatively row paired t-test in the pretherapy and post-treatment NIHSS scoring group for the treatment of group, have significant differences (t=
15.3828, P < 0.01), compare row paired t-test in the pretherapy and post-treatment NIHSS scoring group of control group, there is significant differences (t
=11.5235, P < 0.01)；Two groups of ADL scorings carry out comparison among groups, no significant difference (t=1.88871, P after treatment
> 0.05), show that two groups of neurologic impairments mitigate, but two groups of differences are not significant.
3 safety evaluatios.
Two groups are observed vital sign before and after treatment, and three is big conventional, hepatic and renal function, coagulation function, myocardium enzyme, and electrocardiogram is equal
Without significant change.In therapeutic process, treatment group patient does not also occur apparent adverse reaction, illustrates that Zhuifengtougu capsules are safety
Reliably.
Claims (1)
1. a kind of application of compound Chinese medicinal preparation Zhuifengtougu capsules in the drug of preparation treatment shoulder-hand syndrome after stroke,
The prescription of the compound Chinese medicinal preparation Zhuifengtougu capsules are as follows: aconiti preparata,radix 48.1g, rhizoma cyperi 48.1g processed, Rhizoma Chuanxiong 48.1g, Chinese ephedra
48.1g, wild aconite root 48.1g, gentianae macrophyllae 24g, Radix Angelicae Sinensis 24g, rde bean 48.1g, Rhizoma Et Radix Notopterygii 48.1g, radix paeoniae rubra 48.1g, asarum 48.1g,
Rhizoma Arisaematis (processed) 48.1g, root of Dahurain angelica 48.1g, Radix Glycyrrhizae 48.1g, rhizoma atractylodis macrocephalae 24g, myrrh 9.6g, frankincense 24g, pheretima 48.1g, Fu
Siberian cocklebur 96.2g, ramulus cinnamomi 24g, Rhizoma Gastrodiae 24g, rhizoma nardostachyos 24g, radix saposhnikoviae 24g, cinnabar 38.5g, above 24 taste, cinnabar powder-refining with water or crushing
At impalpable powder；Asarum extracts volatile oil, and the another device of the aqueous solution after distillation is collected, and 22 taste such as remaining Rhizoma Chuanxiong adds water to cook two
Secondary, 2 hours for the first time, second 1 hour, the aqueous solution after collecting decoction and asarum distillation stood 2 hours, filtration, filtrate subtracts
Pressure is condensed into and measures the thick paste that relative density is 1.25 at 60 DEG C, and cinnabar fine powder and appropriate amount of starch is added, and is dried, crushed into thin
Powder mixes, particle is made, dry, sprays into volatile oil, mixes, and is packed into capsule, is made 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825041.3A CN106214990B (en) | 2016-09-18 | 2016-09-18 | Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825041.3A CN106214990B (en) | 2016-09-18 | 2016-09-18 | Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106214990A CN106214990A (en) | 2016-12-14 |
| CN106214990B true CN106214990B (en) | 2019-03-12 |
Family
ID=58075551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610825041.3A Active CN106214990B (en) | 2016-09-18 | 2016-09-18 | Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214990B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671003A (en) * | 2012-06-01 | 2012-09-19 | 湖南省回春堂药业有限公司 | Zhuifengtougu capsules and preparation method thereof |
| CN103301364A (en) * | 2013-07-05 | 2013-09-18 | 李华 | Pharmaceutical composition for treating post-stroke shoulder-hand syndrome |
-
2016
- 2016-09-18 CN CN201610825041.3A patent/CN106214990B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671003A (en) * | 2012-06-01 | 2012-09-19 | 湖南省回春堂药业有限公司 | Zhuifengtougu capsules and preparation method thereof |
| CN103301364A (en) * | 2013-07-05 | 2013-09-18 | 李华 | Pharmaceutical composition for treating post-stroke shoulder-hand syndrome |
Non-Patent Citations (2)
| Title |
|---|
| 追风透骨丸治疗痹证的临床疗效和安全性系统评价;肖微等;《江西中医药大学学报》;20160229;第28卷(第01期);42-46 |
| 追风透骨胶囊联合玻璃酸钠治疗膝骨关节炎的疗效观察;祖洪碧;《中国中医药科技》;20150131;第22卷(第1期);82-83 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106214990A (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | An overview of bee venom acupuncture in the treatment of arthritis | |
| CN100382815C (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
| CN106729580A (en) | Treat the Chinese medicine of apoplexy at acute stage | |
| CN107213422A (en) | A kind of Chinese traditional medicine composition medicine for treating gout | |
| CN103142707B (en) | Traditional Chinese medicine paste or treating chronic soft tissue injury and preparation method thereof | |
| CN106214990B (en) | Application of the Zhuifengtougu capsules as shoulder-hand syndrome after stroke therapeutic agent | |
| CN108578603B (en) | Traditional Chinese medicine compound for treating kidney deficiency and marrow depletion type knee osteoarthritis based on shaoyang bone governing theory and application thereof | |
| CN101518631B (en) | Medicament for treating rheumatoid arthritis | |
| CN108114163A (en) | A kind of drug for treating rheumatoid arthritis and preparation method thereof | |
| CN107041898A (en) | A kind of Chinese medicine preparation and the preparation method of said preparation for osteoarthritis | |
| CN109200158B (en) | Combined medicine for treating Alzheimer disease | |
| CN106214770B (en) | Application of collateral activating and pain relieving capsule in preparation of medicine for treating diabetic peripheral neuropathy | |
| CN102488825B (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN108969729A (en) | A kind of Chinese medicine composition and its preparation method and application for treating vascular dementia | |
| CN108671054A (en) | A kind of waist Chinese medicine composition and preparation method thereof admittedly | |
| CN105326926B (en) | A kind of external medicine preparation that treating muscles along the regular meridians disease, preparation method and application | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN108143929A (en) | A kind of drug for treating vascular dementia | |
| CN102895534A (en) | Chinese medicinal capsule for treating ischemic stroke | |
| CN110123977B (en) | Traditional Chinese medicine composition for treating diabetes combined with gout by external application | |
| CN101559156B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing chronic inflammatory demyelinating polyneuropathy | |
| CN106974958A (en) | Flourish muscle picks up pain side and its production and use | |
| CN106389602A (en) | Pharmaceutical composition for treating syndromes of phlegm heat and bowel repletion of stroke and preparation method of pharmaceutical composition | |
| Cai | Add-on benefit of Chinese medicine for post-stroke spasticity: current state of evidence and future research priorities | |
| CN116549530A (en) | A capsule for treating liver and kidney deficiency type diseases, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 410330 No. 109 Kangtian Road, Changsha National Biological Industrial Base, Changsha City, Hunan Province Patentee after: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Address before: 410330 No. 109 Kangtian Road, Changsha National Biological Industrial Base, Changsha City, Hunan Province Patentee before: HUNAN TIANDI HENGYI PHARMACEUTICAL CO.,LTD. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Zhuifengtougu capsules serving as drug for treating shoulder-hand syndrome after cerebral stroke Effective date of registration: 20190625 Granted publication date: 20190312 Pledgee: Bank of Changsha Limited by Share Ltd. Liuyang branch Pledgor: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Registration number: 2019430000057 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20190312 Pledgee: Bank of Changsha Limited by Share Ltd. Liuyang branch Pledgor: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Registration number: 2019430000057 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Zhuifeng Tonggu Capsule as a Treatment Drug for Shoulder Hand Syndrome After Stroke Granted publication date: 20190312 Pledgee: Bank of Changsha Limited by Share Ltd. Liuyang branch Pledgor: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980011973 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |